Long non-coding RNA LEISA promotes progression of lung adenocarcinoma via enhancing interaction between STAT3 and IL-6 promoter
- PMID: 33859372
- DOI: 10.1038/s41388-021-01769-7
Long non-coding RNA LEISA promotes progression of lung adenocarcinoma via enhancing interaction between STAT3 and IL-6 promoter
Abstract
Long non-coding RNAs (lncRNAs) are emerging as a new class of regulators for a variety of biological processes and have been suggested to play pivotal roles in cancer development and progression. Our current study found that a lncRNA, designated enhancing IL-6/STAT3 signaling activation (LEISA, ENST00000603468), functioned as an oncogenic lncRNA in lung adenocarcinoma (LAD), a major form of non-small cell lung carcinoma, which is one of the most frequently diagnosed malignancies with high morbidity and mortality worldwide, and was involved in the regulation of STAT3 induced IL-6 transcription. Our data showed that LEISA was highly expressed in, and correlated with the clinical progression and prognosis of LAD. Ectopic expression of LEISA promoted the proliferation and suppressed apoptosis of LAD cells in vitro and in vivo. Mechanistically, we demonstrated that LEISA recruited STAT3 to bind the promoter of IL-6 and upregulated IL-6 expression. Taken together, our work identifies LEISA as a potential diagnostic biomarker and therapeutic target for LAD.
Similar articles
-
lncRNA H19 promotes viability and epithelial-mesenchymal transition of lung adenocarcinoma cells by targeting miR-29b-3p and modifying STAT3.Int J Oncol. 2019 Mar;54(3):929-941. doi: 10.3892/ijo.2019.4695. Epub 2019 Jan 24. Int J Oncol. 2019. PMID: 30747209 Free PMC article.
-
Long non-coding RNA linc00665 promotes lung adenocarcinoma progression and functions as ceRNA to regulate AKR1B10-ERK signaling by sponging miR-98.Cell Death Dis. 2019 Jan 28;10(2):84. doi: 10.1038/s41419-019-1361-3. Cell Death Dis. 2019. PMID: 30692511 Free PMC article.
-
LNRRIL6, a novel long noncoding RNA, protects colorectal cancer cells by activating the IL-6-STAT3 pathway.Mol Oncol. 2019 Nov;13(11):2344-2360. doi: 10.1002/1878-0261.12538. Epub 2019 Sep 30. Mol Oncol. 2019. PMID: 31246342 Free PMC article.
-
Dual relationship between long non-coding RNAs and STAT3 signaling in different cancers: New insight to proliferation and metastasis.Life Sci. 2021 Apr 1;270:119006. doi: 10.1016/j.lfs.2020.119006. Epub 2021 Jan 6. Life Sci. 2021. PMID: 33421521 Review.
-
Noncoding RNAs as regulators of STAT3 pathway in gastrointestinal cancers: Roles in cancer progression and therapeutic response.Med Res Rev. 2023 Sep;43(5):1263-1321. doi: 10.1002/med.21950. Epub 2023 Mar 23. Med Res Rev. 2023. PMID: 36951271 Review.
Cited by
-
IL-6-induced long noncoding RNA MIR3142HG promotes tumorigenesis by interacting with thioredoxin-1 and STAT3 in human colorectal cancer.Cell Mol Biol Lett. 2025 May 22;30(1):61. doi: 10.1186/s11658-025-00742-6. Cell Mol Biol Lett. 2025. PMID: 40405062 Free PMC article.
-
LincRNA00612 inhibits apoptosis and inflammation in LPS-induced BEAS-2B cells via enhancing interaction between p-STAT3 and A2M promoter.PeerJ. 2023 Mar 2;11:e14986. doi: 10.7717/peerj.14986. eCollection 2023. PeerJ. 2023. PMID: 36883061 Free PMC article.
-
LncRNA RCAT1 promotes tumor progression and metastasis via miR-214-5p/E2F2 axis in renal cell carcinoma.Cell Death Dis. 2021 Jul 9;12(7):689. doi: 10.1038/s41419-021-03955-7. Cell Death Dis. 2021. PMID: 34244473 Free PMC article.
-
A novel melanoma prognostic model based on the ferroptosis-related long non-coding RNA.Front Oncol. 2022 Oct 12;12:929960. doi: 10.3389/fonc.2022.929960. eCollection 2022. Front Oncol. 2022. PMID: 36313708 Free PMC article.
-
Knockdown of RNF183 suppressed proliferation of lung adenocarcinoma cells via inactivating the STAT3 signaling pathway.Cell Cycle. 2022 May;21(9):948-960. doi: 10.1080/15384101.2022.2035617. Epub 2022 Feb 1. Cell Cycle. 2022. Retraction in: Cell Cycle. 2024 Sep-Oct;23(17-20):i. doi: 10.1080/15384101.2024.2370723. PMID: 35104174 Free PMC article. Retracted.
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer J clinicians. 2018;68:394–424.
-
- Liu WJ, Du Y, Wen R, Yang M, Xu J. Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. Pharmacol therapeutics. 2020;206:107438. - DOI
-
- Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. Non-small cell lung cancer, version 6.2015. J Natl Compr Cancer Netw: JNCCN. 2015;13:515–24. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous